Access Pharmaceuticals Expands ProLindac Clinical Trial Sites

Armen Hareyan's picture

ProLindac Clinical Trial

Access Pharmaceuticals, Inc. announced that it has continued to expand the number of clinical trial sites for its on-going Phase 2 trial of ProLindac in patients with recurrent platinum-sensitive ovarian cancer.


The number of sites opened has now reached 11, up from two initial sites when the trial was commenced last year. The additional sites allow for the potential of more rapid patient accrual.

"We are pleased with the increase in hospitals that are interested in participating in our ProLindac ovarian cancer trial," said Stephen R. Seiler, Access' Chief Executive Officer. "The expanded number of sites also gives us the advantage of being able to draw from a larger potential patient population for trial enrolment."

ProLindac, is a novel DACH platinum prodrug which has been shown to be active in a wide variety of solid tumors in both preclinical models and in human trials. Access believes ProLindac's unique molecular design potentially could eliminate some of the toxic neurological side effects seen in the currently marketed DACH platinum, oxaliplatin, which has sales in excess of $2 billion. In a Phase 1 clinical study, at least five times more DACH platinum could be administered to patients with ProLindac(TM) than oxaliplatin before the onset of toxicity.